Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis
Primary Purpose
Necrotizing Enterocolitis, Enterocolitis, Necrotizing
Status
Unknown status
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Heat Inactivated probiotics
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Necrotizing Enterocolitis
Eligibility Criteria
Inclusion Criteria:
- Preterm neonates
- ≤1500 gm birth weight
Exclusion Criteria:
- Infants who are not deemed likely to survive more than one week;
- Infants who are not started on enteral feeds by one week of age;
- Infants who have significant congenital malformations or other gastrointestinal problem
Sites / Locations
- Neonatal Intensive Care Unit - Shaare Zedek Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Control Group
Treatment Group
Arm Description
Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
Dietary Supplement: Heat Inactivated Probiotics 1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula.
Outcomes
Primary Outcome Measures
Necrotizing Enterocolitis, Bell Stage 2 or above, or Death
Necrotizing Enterocolitis diagnosis will be based on clinical and radiographic criteria
Secondary Outcome Measures
Increased Urine IFABP Levels
Increased Fecal Calprotectin Levels
Full Information
NCT ID
NCT02796703
First Posted
May 22, 2016
Last Updated
June 15, 2016
Sponsor
Shaare Zedek Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02796703
Brief Title
Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis
Official Title
Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis (NEC) in Premature Neonates
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Unknown status
Study Start Date
June 2016 (undefined)
Primary Completion Date
July 2020 (Anticipated)
Study Completion Date
September 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaare Zedek Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Prophylactic probiotics have been shown to decrease the incidence of Necrotizing Enterocolitis (NEC) in premature neonates. However, there is some resistance to giving live bacteria to small babies. Based on animal data, the investigators hypothesized that heat inactivated probiotics would also reduce NEC.
Detailed Description
Preterm neonates, <1500 gm birth weight will potentially be candidates for study and will be recruited when they begin enteral feeding. The infants will be prospectively and randomly assigned to one of two groups:
Treatment group - to receive daily inactivated probiotic prophylaxis starting with the initiation of feeds. 1 tsp powder will be diluted in 2 cc of mother's milk when possible or in Similac Special Care formula 24 cal when mother's milk is not available; and
Control group - to receive 2 cc/day of placebo similarly diluted. Supplements will be continued until the infant tolerates enteral feeds of 100 cc/kg/day or reaches 35 weeks post conceptual age (whichever comes LAST). Biotikid, a probiotic mixture, will be heated to 100 degrees C for 10 minutes. Babies will be followed clinically for signs of NEC, and with urine intestinal fatty acid binding protein (IFABP) and fecal calprotectin levels.
The investigators primary aim is to demonstrate that premature neonates who are treated prophylactically with heat inactivated probiotics will have less necrotizing enterocolitis when compared to age matched infants given placebo.
The investigators secondary objectives are to demonstrate the following:
That the decrease in NEC will coincide with improved intestinal barrier integrity, as reflected by levels of:
I-FABP in urine
Fecal Calprotectin
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Necrotizing Enterocolitis, Enterocolitis, Necrotizing
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Description
Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
Arm Title
Treatment Group
Arm Type
Active Comparator
Arm Description
Dietary Supplement: Heat Inactivated Probiotics
1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula.
Intervention Type
Dietary Supplement
Intervention Name(s)
Heat Inactivated probiotics
Intervention Description
Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
2 cc of milk will be given to control group
Primary Outcome Measure Information:
Title
Necrotizing Enterocolitis, Bell Stage 2 or above, or Death
Description
Necrotizing Enterocolitis diagnosis will be based on clinical and radiographic criteria
Time Frame
Birth until 40 weeks post-conceptional age
Secondary Outcome Measure Information:
Title
Increased Urine IFABP Levels
Time Frame
Weekly, from date of randomization until full enteral feeds (100 cc/kg/day) achieved or until death or necrotizing enterocolitis is diagnosed, whichever comes first until 37 weeks postconceptional age
Title
Increased Fecal Calprotectin Levels
Time Frame
Weekly, from date of randomization until full enteral feeds (100 cc/kg/day) achieved or until death or necrotizing enterocolitis is diagnosed, whichever comes first until 37 weeks postconceptional age
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Hours
Maximum Age & Unit of Time
7 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Preterm neonates
≤1500 gm birth weight
Exclusion Criteria:
Infants who are not deemed likely to survive more than one week;
Infants who are not started on enteral feeds by one week of age;
Infants who have significant congenital malformations or other gastrointestinal problem
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cathy Hammerman, MD
Phone
0508685238
Email
cathyh@ekmd.huji.ac.il
First Name & Middle Initial & Last Name or Official Title & Degree
Alona Bin-Nun, MD
Phone
0508685757
Email
alona.binnun@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cathy Hammerman, MD
Organizational Affiliation
Shaare Zedek Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neonatal Intensive Care Unit - Shaare Zedek Medical Center
City
Jerusalem
ZIP/Postal Code
91031
Country
Israel
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
20506712
Citation
Awad H, Mokhtar H, Imam SS, Gad GI, Hafez H, Aboushady N. Comparison between killed and living probiotic usage versus placebo for the prevention of necrotizing enterocolitis and sepsis in neonates. Pak J Biol Sci. 2010 Mar 15;13(6):253-62. doi: 10.3923/pjbs.2010.253.262.
Results Reference
background
Learn more about this trial
Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis
We'll reach out to this number within 24 hrs